HCPCS Code Applications and Approvals: January 2023
Quarterly archive · CMS Level II HCPCS50 coding decisions took effect January 1, 2023
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Third Quarter 2022 coding cycle, which took effect January 1, 2023.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
January 2023
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| C9046 | Cocaine Hydrochloride Nasal Solution (Goprelto) Cocaine hydrochloride nasal solution (goprelto), 1 mg | — Intranasal | — | Revise | |
| C9143 | Cocaine Hydrochloride Nasal Solution (Numbrino) Cocaine hydrochloride nasal solution (numbrino), 1 mg | — Intranasal | — | Establish | |
| J0131 | Acetaminophen Injection, acetaminophen, not otherwise specified, 10 mg | — | — | Revise | |
| J0134 | Acetaminophen (Fresenius Kabi) Injection, acetaminophen (fresenius kabi) not therapeutically equivalent to J0131, 10 mg | — | — | Establish | |
| J0136 | Acetaminophen (B Braun) Injection, acetaminophen (b braun) not therapeutically equivalent to J0131, 10 mg | — | — | Establish | |
| J0173 | Epinephrine (Belcher) Injection, epinephrine (belcher) not therapeutically equivalent to J0171, 0.1 mg | — | — | Establish | |
| J0225 | AMVUTTRA Injection, vutrisiran, 1 mg | Alnylam Pharmaceuticals, Inc. Subcutaneous | — | Establish | |
| J0283 | Amiodarone Hydrochloride (Nexterone) 505(b)(2) Injection, amiodarone hydrochloride (nexterone), 30 mg | — | — | Establish | |
| J0610 | Calcium Gluconate (Fresenius Kabi) Injection, calcium gluconate (fresenius kabi), per 10 ml | — | — | Revise | |
| J0611 | Calcium Gluconate (Wg Critical Care) Injection, calcium gluconate (wg critical care), per 10 ml | — | — | Establish | |
| J0689 | Cefazolin Sodium (Baxter) 505(b)(2) Injection, cefazolin sodium (baxter), not therapeutically equivalent to J0690, 500 mg | — | — | Establish | |
| J0701 | Cefepime Hydrochloride (Baxter) 505(b)(2) Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg | — | — | Establish | |
| J0703 | Cefepime Hydrochloride (B Braun) 505(b)(2) Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg | — | — | Establish | |
| J0877 | Daptomycin (Hospira) Injection, daptomycin (hospira), not therapeutically equivalent to J0878, 1 mg | — | — | Establish | |
| J0891 | Argatroban (Accord) 505(b)(2) Injection, argatroban (accord), not therapeutically equivalent to J0883, 1 mg (for non-esrd use) | — | — | Establish | |
| J0892 | Argatroban (Accord) 505(b)(2) Injection, argatroban (accord), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis) | — | — | Establish | |
| J0893 | Decitabine (Sun Pharma) 505(b)(2) Injection, decitabine (sun pharma) not therapeutically equivalent to J0894, 1 mg | — | — | Establish | |
| J0898 | Argatroban (Auromedics) 505(b)(2) Injection, argatroban (auromedics), not therapeutically equivalent to J0883, 1 mg (for non-esrd use) | — | — | Establish | |
| J0899 | Argatroban (Auromedics) 505(b)(2) Injection, argatroban (auromedics), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis) | — | — | Establish | |
| J1456 | Fosaprepitant (Teva) 505(b)(2) Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg | — | — | Establish | |
| J1574 | Ganciclovir Sodium (Exela) 505(b)(2) Injection, ganciclovir sodium (exela) not therapeutically equivalent to J1570, 500 mg | — | — | Establish | |
| J1611 | Glucagon Hydrochloride (Fresenius Kabi) Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to J1610, per 1 mg | — | — | Establish | |
| J1643 | Heparin Sodium (Pfizer) 505(b)(2) Injection, heparin sodium (pfizer), not therapeutically equivalent to J1644, per 1000 units | — | — | Establish | |
| J1954 | Leuprolide Acetate 505(b)(2) Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg | Cipla USA Inc. Intramuscular | — | Establish | |
| J2021 | Linezolid (Hospira) 505(b)(2) Injection, linezolid (hospira) not therapeutically equivalent to J2020, 200 mg | — | — | Establish | |
| J2184 | Meropenem (B. Braun) 505(b)(2) Injection, meropenem (b. braun) not therapeutically equivalent to J2185, 100 mg | — | — | Establish | |
| J2247 | Micafungin Sodium (Par Pharm) Injection, micafungin sodium (par pharm) not therapeutically equivalent to J2248, 1 mg | — | — | Establish | |
| J2251 | Midazolam Hydrochloride (Wg Critical Care) Injection, midazolam hydrochloride (wg critical care) not therapeutically equivalent to J2250, per 1 mg | — | — | Establish | |
| J2272 | Morphine Sulfate (Fresenius Kabi) 505(b)(2) Injection, morphine sulfate (fresenius kabi) not therapeutically equivalent to J2270, up to 10 mg | — | — | Establish | |
| J2281 | Moxifloxacin (Fresenius Kabi) Injection, moxifloxacin (fresenius kabi) not therapeutically equivalent to J2280, 100 mg | — | — | Establish | |
| J2311 | Naloxone Hydrochloride (Zimhi) Injection, naloxone hydrochloride (zimhi), 1 mg | — | — | Establish | |
| J2327 | SKYRIZI Injection, risankizumab-rzaa, intravenous, 1 mg | AbbVie Intravenous/Subcutaneous | — | Establish | |
| J2400 | Chloroprocaine Hydrochloride Injection, chloroprocaine hydrochloride, per 30 ml | — | Replaced byJ2401 | Discontinue | |
| J2401 | Chloroprocaine Hydrochloride 505(b)(2) Injection, chloroprocaine hydrochloride, per 1 mg | — | ReplacesJ2400 | Establish | |
| J2402 | Chloroprocaine Hydrochloride (Clorotekal) 505(b)(2) Injection, chloroprocaine hydrochloride (clorotekal), per 1 mg | — | — | Establish | |
| J3244 | Tigecycline (Accord) 505(b)(2) Injection, tigecycline (accord) not therapeutically equivalent to J3243, 1 mg | — | — | Establish | |
| J3371 | Vancomycin Hcl (Mylan) Injection, vancomycin hcl (mylan) not therapeutically equivalent to J3370, 500 mg | — | — | Establish | |
| J3372 | Vancomycin Hcl (Xellia) Injection, vancomycin hcl (xellia) not therapeutically equivalent to J3370, 500 mg | — | — | Establish | |
| J9041 | Bortezomib 505(b)(2) Injection, bortezomib, 0.1 mg | — | — | Revise | |
| J9044 | Bortezomib Injection, bortezomib, not otherwise specified, 0.1 mg | — | — | Discontinue | |
| J9046 | Bortezomib (Dr. Reddy’s) 505(b)(2) Injection, bortezomib, (dr. reddy’s), not therapeutically equivalent to J9041, 0.1 mg | — | — | Establish | |
| J9048 | Bortezomib (Fresenius Kabi) 505(b)(2) Injection, bortezomib (fresenius kabi), not therapeutically equivalent to J9041, 0.1 mg | — | — | Establish | |
| J9049 | Bortezomib (Hospira) Injection, bortezomib (hospira), not therapeutically equivalent to J9041, 0.1 mg | — | — | Establish | |
| J9314 | Pemetrexed (Teva) 505(b)(2) Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg | — | — | Establish | |
| J9393 | Fulvestrant (Teva) Injection, fulvestrant (teva) not therapeutically equivalent to J9395, 25 mg | — | — | Establish | |
| J9394 | Fulvestrant (Fresenius Kabi) Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to J9395, 25 mg | — | — | Establish | |
| Q4262 | Dual Layer Impax Membrane Dual layer impax membrane, per square centimeter | Legacy Medical Consultants | — | Establish | |
| Q4263 | SurGraft TL Surgraft tl, per square centimeter | Surgenex, LLC | — | Establish | |
| Q4264 | Cocoon Membrane Cocoon membrane, per square centimeter | Pinnacle Transplant Technologies | — | Establish | |
| Q5126 | ALYMSYS Biosimilar Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Amneal Pharmaceuticals Intravenous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Third Quarter 2022 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
